BioSpace News Archive

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method (“Rapid Test Kit”).

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately.

KemPharm, Inc. announced that a manuscript summarizing the results of three clinical studies involving serdexmethylphenidate, KemPharm’s prodrug of dexmethylphenidate, was published in the peer-reviewed journal, Current Medical Research & Opinion.

Company to host virtual investor R&D event on Monday, June 6, 2022 at 4:05 PM EDT featuring covalent menin inhibitor, BMF-219, as a potential novel treatment for type 2 diabetes.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-333 for the treatment of Peripheral T-cell Lymphoma (PTCL).

Legend Biotech today reported its first quarter 2022 unaudited financial results.

Saneso Inc., a leading US developer of next gen endoscope systems announces today the US Food and Drug Administration (FDA) has granted 510(k) clearance of its novel integrated 360° field of view colonoscope.

Royal Biologics (Hackensack, NJ), a company specializing in Advanced Cellular Technologies & Enhanced Autologous Healing, announces today the FDA 510K regulatory clearance and U.S. commercial launch of the MAXX™-BMC system.

Sichuan Kelun-Biotech Biopharmaceutical Co, Ltd. and Levena Biopharma, a subsidiary of Sorrento Therapeutics, Inc., announced the planned presentation of A166 data in patients with HER2-expressing locally advanced or metastatic solid tumors at the 2022 Annual Meeting of ASCO, the American Society of Clinical Oncology, to be held on June 3-7 in Chicago, IL.